Browse > Article
http://dx.doi.org/10.3339/jkspn.2010.14.1.32

Mesenchymal Stem Cells Ameliorate Adriamycin Induced Proteinuric Nephropathy  

Kang, Hee-Gyung (Department of Pediatrics, Seoul National University Hospital)
Park, So-Yeon (Department of Pathology, Seoul National University College of Medicine)
Ha, Il-Soo (Department of Pediatrics, Seoul National University Hospital)
Cheong, Hae-Il (Department of Pediatrics, Seoul National University Hospital)
Choi, Yong (Department of Pediatrics, Seoul National University Hospital)
Publication Information
Childhood Kidney Diseases / v.14, no.1, 2010 , pp. 32-41 More about this Journal
Abstract
Purpose : Glomerulonephropathy (GN) often manifests as proteinuria and progresses to chronic renal failure without specific therapy. Mesenchymal stem cell (MSC) has been tried as a therapeutic agent in experimental GN, and previous studies showed that administration of MSC concomitantly to the insult inducing GN or via intra-renal administration ameliorated proteinuria. The purpose of this study was to test the therapeutic potential of MSC administered via intravenous route at the time of clinically evident proteinuria. Methods : MSCs were administered intravenously via tail vain into the mice with adriamycin (ADR) induced nephropathy (ADR-GN), two weeks after ADR injection when massive proteinuria was evident. To test the capacity of MSC modulate the cytokine production in the inflammatory milieu, the concentrations of IFN-$\gamma$ and IL-10 were measured in the supernatant of in vitro mixed lymphocyte culture (MLC) with or without additional MSC. Results : MSCs administered intravenously into the proteinuric mice with ADR-GN accelerated the recovery of this experimental GN with disappearance of proteinuria in two weeks when the saline treated (control) mice still showed significant proteinuria. The mice treated with MSC also had a tendency of better survival. Addition of MSC decreased IFN-$\gamma$ and increased IL-10 in the supernatant of MLC. Conclusion : This study showed that MSC had a therapeutic potential even when administered in a more clinically relevant setting into a proteinuric glomerulonephropathy model. Further study to verify the mechanism and long-term safety of this phenomenon is required.
Keywords
Glomerulonephropathy; Immune modulation; Mesenchymal stem cell; Proteinuria;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kunter U, Rong S, Boor P, Eitner F, Muller-Newen G, Djuric Z, et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 2007; 18:1754-64.   DOI   ScienceOn
2 Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (mscs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-8.   DOI   ScienceOn
3 Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, et al. Immunostimulatory tim-1-specific antibody deprograms tregs and prevents transplant tolerance in mice. J Clin Invest 2008;118:735-41.   DOI   ScienceOn
4 Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen 4a3-deficient mice. Kidney Int 2006;70: 121-9.   DOI   ScienceOn
5 Togel F, Yang Y, Zhang P, Hu Z, Westenfelder C. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol 2008;295: F315-21.   DOI   ScienceOn
6 Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003;108:863-8.   DOI   ScienceOn
7 Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce t-cell unresponsiveness. Blood 2005;105:2214-9.   DOI   ScienceOn
8 Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 2009;18:475-85.   DOI   ScienceOn
9 Kunter U, Rong S, Djuric Z, Boor P, Muller-Newen G, Yu D, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:2202-12.   DOI   ScienceOn
10 Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009;18:683-92.   DOI   ScienceOn
11 Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.   DOI   ScienceOn
12 Wang Y, Feng X, Bao S, Yi S, Kairaitis L, Tay YC, et al. Depletion of cd4(+) t cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy. Kidney Int 2001;59:975-84.   DOI   ScienceOn
13 Rangan GK, Wang Y, Tay YC, Harris DC. Cytokine gene expression in adriamycin nephropathy: Effects of antioxidant nuclear factor kappab inhibitors in established disease. Nephron 2000;86:482-90.   DOI   ScienceOn
14 Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004;14:1035-41.
15 Morigi M, Benigni A, Remuzzi G, Imberti B. The regenerative potential of stem cells in acute renal failure. Cell Transplant 2006; 15 Suppl 1:S111-7.   DOI
16 Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual t cells throughout activation and clonal expansion. Signals from t cell receptor and cd28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997;100:3173-83.   DOI   ScienceOn
17 Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990;86: 453-62.   DOI
18 Frank MH, Sayegh MH. Immunomodulatory functions of mesenchymal stem cells. Lancet 2004;363:1411-2.   DOI   ScienceOn
19 Magnasco A, Corselli M, Bertelli R, Ibatici A, Peresi M, Gaggero G, et al. Mesenchymal stem cells protective effect in adriamycin model of nephropathy. Cell Transplant 2008;17:1157-67.   DOI   ScienceOn
20 Wang Y, Mahajan D, Tay YC, Bao S, Spicer T, Kairaitis L, et al. Partial depletion of macrophages by ed7 reduces renal injury in adriamycin nephropathy. Nephrology (Carlton) 2005;10:470-7.   DOI   ScienceOn
21 Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815-22.   DOI   ScienceOn
22 Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase ii study. Lancet 2008;371:1579-86.   DOI
23 Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiationindependent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-42.   DOI   ScienceOn
24 Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989;135:719-33.
25 Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-96.   DOI   ScienceOn
26 Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201.   DOI   ScienceOn